- Home
- KVAC vs ABEO Comparison
KVAC vs ABEO Comparison
Compare KVAC & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KVAC
- ABEO
- Stock Information
- Founded
- KVAC 2021
- ABEO N/A
- Country
- KVAC United States
- ABEO United States
- Employees
- KVAC N/A
- ABEO N/A
- Industry
- KVAC
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- KVAC
- ABEO Health Care
- Exchange
- KVAC Nasdaq
- ABEO Nasdaq
- Market Cap
- KVAC 212.1M
- ABEO 237.4M
- IPO Year
- KVAC 2023
- ABEO 1980
- Fundamental
- Price
- KVAC $11.18
- ABEO $5.32
- Analyst Decision
- KVAC
- ABEO Strong Buy
- Analyst Count
- KVAC 0
- ABEO 5
- Target Price
- KVAC N/A
- ABEO $17.00
- AVG Volume (30 Days)
- KVAC 6.1K
- ABEO 332.6K
- Earning Date
- KVAC 01-01-0001
- ABEO 03-25-2025
- Dividend Yield
- KVAC N/A
- ABEO N/A
- EPS Growth
- KVAC N/A
- ABEO N/A
- EPS
- KVAC N/A
- ABEO N/A
- Revenue
- KVAC N/A
- ABEO N/A
- Revenue This Year
- KVAC N/A
- ABEO N/A
- Revenue Next Year
- KVAC N/A
- ABEO $15,721.96
- P/E Ratio
- KVAC $29.22
- ABEO N/A
- Revenue Growth
- KVAC N/A
- ABEO 147.52
- 52 Week Low
- KVAC $10.42
- ABEO $3.05
- 52 Week High
- KVAC $11.19
- ABEO $8.87
- Technical
- Relative Strength Index (RSI)
- KVAC 69.39
- ABEO 53.21
- Support Level
- KVAC $11.14
- ABEO $4.92
- Resistance Level
- KVAC $11.14
- ABEO $5.45
- Average True Range (ATR)
- KVAC 0.00
- ABEO 0.30
- MACD
- KVAC -0.00
- ABEO 0.03
- Stochastic Oscillator
- KVAC 83.33
- ABEO 71.43
About KVAC Keen Vision Acquisition Corporation
Keen Vision Acquisition Corp is a blank check company.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.